Last reviewed · How we verify
SABER-Bupivacaine Treatment 2a — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
SABER-Bupivacaine Treatment 2a (SABER-Bupivacaine Treatment 2a) — Durect.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SABER-Bupivacaine Treatment 2a TARGET | SABER-Bupivacaine Treatment 2a | Durect | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SABER-Bupivacaine Treatment 2a CI watch — RSS
- SABER-Bupivacaine Treatment 2a CI watch — Atom
- SABER-Bupivacaine Treatment 2a CI watch — JSON
- SABER-Bupivacaine Treatment 2a alone — RSS
Cite this brief
Drug Landscape (2026). SABER-Bupivacaine Treatment 2a — Competitive Intelligence Brief. https://druglandscape.com/ci/saber-bupivacaine-treatment-2a. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab